CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 26 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00621946
NCT00621946Phase 4Completed
CompareCT.gov

Escitalopram in the Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

University of Texas Southwestern Medical Center·interventional·Posted Feb 22, 2008·Updated Feb 4, 2014

In Brief

A Phase 4 clinical trial evaluating Placebo and Escitalopram for Severe Asthma and Moderate or Severe Major Depressive Disorder. Completed, enrolled 26 participants across 1 site.

Detailed Summary

The purpose is to determine if: 1) Escitalopram treatment will be associated with less oral corticosteroid use than placebo in outpatients with severe asthma and moderate or severe major depressive disorder (MDD). 2) Escitalopram treatment will be associated with greater improvement in asthma symptoms than placebo in outpatients with severe asthma and moderate or severe MDD. 3) Escitalopram treatment will be associated with greater depressive symptom remission rates than placebo in outpatients with severe asthma and moderate or severe MDD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Asthma, Moderate or Severe Major Depressive Disorder
CountriesUnited States
CollaboratorsForest Laboratories

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 22, 2008
Enrollment StartMar 1, 2008
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.4 years ago

Interventions

Placebodrug

Placebo Matching Escitalopram

Escitalopramdrug

Active Escitalopram